Characteristics of Patients With Hematologic Cancer and Fusariosis: Comparison Between Responders and Nonresponders
| Characteristic . | Responders . | Nonresponders . |
|---|---|---|
| . | (n = 13) . | (n = 30) . |
| Age (year) | ||
| Median | 52 | 42 |
| Range | 22-75 | 14-71 |
| Sex (males/females) | 7/6 | 19/11 |
| Underlying disease (n) | ||
| Acute nonlymphocytic leukemia | 6 | 17 |
| Acute lymphocytic leukemia | 4 | 3 |
| Other hematologic disorders | 3 | 10 |
| Active underlying disease at start of infection (n) | 10 | 28 |
| Active underlying disease at end of infection (n) | 0 | 27 |
| Patients with neutropenia at start of infection (n) | 9 | 27 |
| Patients with neutropenia at end of infection (n) | 0 | 30 |
| Duration of neutropenia (d) | ||
| Median | 23 | 26 |
| Range | 0-55 | 5-65 |
| Type of transplant (12 patients) (n) | ||
| Autologous | 0 | 3 |
| Allogeneic | 3 | 6 |
| Patients with GVDH at start of infection* (n) | 0 | 4 |
| Prior history of invasive fungal infection (n) | 0 | 7 |
| Cumulative dose of AmB (mg) | ||
| Median | 1,380 | 775 |
| Range | 720-2,740 | 120-4,295 |
| Cumulative dose of liposomal preparations of AmB (mg) | ||
| Median | 7,100 | 5,325 |
| Range | 4,215-31,525 | 1,700-28,995 |
| Patients receiving growth factors (n) | 7 | 10 |
| Start of infection after BMT (d) | ||
| Median | 30 | 46 |
| Range | 13-73 | 7-151 |
| Patients receiving WBC transfusions (G-CSF–elicited) (n) | 3 | 4 |
| Extent of infection (n) | ||
| Disseminated | 11 | 29 |
| Limited† | 2 | 1 |
| Characteristic . | Responders . | Nonresponders . |
|---|---|---|
| . | (n = 13) . | (n = 30) . |
| Age (year) | ||
| Median | 52 | 42 |
| Range | 22-75 | 14-71 |
| Sex (males/females) | 7/6 | 19/11 |
| Underlying disease (n) | ||
| Acute nonlymphocytic leukemia | 6 | 17 |
| Acute lymphocytic leukemia | 4 | 3 |
| Other hematologic disorders | 3 | 10 |
| Active underlying disease at start of infection (n) | 10 | 28 |
| Active underlying disease at end of infection (n) | 0 | 27 |
| Patients with neutropenia at start of infection (n) | 9 | 27 |
| Patients with neutropenia at end of infection (n) | 0 | 30 |
| Duration of neutropenia (d) | ||
| Median | 23 | 26 |
| Range | 0-55 | 5-65 |
| Type of transplant (12 patients) (n) | ||
| Autologous | 0 | 3 |
| Allogeneic | 3 | 6 |
| Patients with GVDH at start of infection* (n) | 0 | 4 |
| Prior history of invasive fungal infection (n) | 0 | 7 |
| Cumulative dose of AmB (mg) | ||
| Median | 1,380 | 775 |
| Range | 720-2,740 | 120-4,295 |
| Cumulative dose of liposomal preparations of AmB (mg) | ||
| Median | 7,100 | 5,325 |
| Range | 4,215-31,525 | 1,700-28,995 |
| Patients receiving growth factors (n) | 7 | 10 |
| Start of infection after BMT (d) | ||
| Median | 30 | 46 |
| Range | 13-73 | 7-151 |
| Patients receiving WBC transfusions (G-CSF–elicited) (n) | 3 | 4 |
| Extent of infection (n) | ||
| Disseminated | 11 | 29 |
| Limited† | 2 | 1 |